A Phase 2b, open-label, single-arm study of ZW25 monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers
The purpose of this study is to learn what effects the study drug, ZW25, has on the body and on cancer cells.
HER2 Biliary Tract Cancer
Male or Female at least 18 years or older
Must have HER2 biliary tract cancer
18 - 100
Healthy Volunteers Needed
Duration of Participation
You can remain in the study as long as you are not getting worse or having bad side effects. After you finish the study, the study team will continue to follow your condition by phone calls every 3 months.
Knight Clinical Trials Information Line